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Intra-nodal naevi (INN) identified during assessment of a sentinel lymph node for 
melanoma are not an uncommon finding. Little is known about their clinical signifi-
cance. Patients with INN are treated as sentinel node biopsy (SNB) negative cur-




353 melanoma patients who underwent a SNB between November 1999 and June 
2012 were retrospectively analysed from a prospectively collected database. The pa-
tients were divided into SNB negative, INN, isolated tumour cells (ITC) and SNB pos-
itive groups. Outcome measures of nodal recurrence, distal recurrence and survival 
were used to assess the differences between the groups. 
 
Results 
203 patients were SNB negative, 103 were positive of which 13 had ITC, 47 had INN 
(13%). Overall median follow up was 2.3 years (range 0.1 – 14.1 years). Our data 
demonstrated a statistically significant survival benefit for patients who had an INN 
compared to the SNB positive and ITC group. INN patients also had significantly bet-
ter nodal and regional recurrence compared to SNB positive patients. There was no 
difference between INN and SNB negative patients. 
 
Conclusion 
We have clinically demonstrated that patients with INN on SNB can be adequately 
treated as SNB negative patients.  
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Introduction 
Sentinel node biopsy (SNB) is a well established and accepted staging tool for malig-
nant melanoma (MM) patients. It involves a triple diagnostic technique, using lym-
phoscintography, blue dye and radio colloid with gamma probe detection. SNB al-
lows upstaging of patients with isolated melanoma cells and micrometastasis which 
can permit early intervention with nodal basin clearance before potential progression 
into palpable stage III disease. However the benefits of early intervention for mi-
crometasis have not been proven by clinical trial and await the results of the Multi-
center selective lymphadenectomy trial II (MSLT-II). 
 
The detection of micrometastases and isolated tumour cells within sentinel node bi-
opsies has been improved by advances in immunohistochemistry techniques. INN 
(also referred to as nodal naevi and naevus cell aggregates) are not an uncommon 
finding in sentinel node biopsies, particularly in axillary nodes (1-3). They are less 
frequently found in lymphadenectomy specimens, most likely due to the more thor-
ough sectioning techniques used in SNB. INN are often found as isolated clusters of 
normal-appearing melanocytes within the capsule, trabeculae, and rarely the paren-
chyma or lymphatic channels, of a lymph node (3,4). A histological example of an 
INN is shown in Figure 1. INN can be present in several malignancies including 
breast carcinoma, squamous cell carcinoma of the skin and most commonly mela-
noma, with the incidence of INN in all malignancies reported as 1-24% (2,5,6). 
 
Two controversial hypotheses regarding their origin exist: I) there is regional embolic 
drainage of melanocytes from a naevus to a lymph node via the lymphatics (7,8); II) 
embryological neural crest derived melanocytes are transported to lymph nodes dur-
ing in-utero migration (7,9). 
 
Histologically it can be difficult to differentiate INN from nodal metastases and a com-
bination of immunohistochemistry, location and morphology must be used although 
this is not consistently reliable. This provides significant diagnostic challenges where 
false positive and negative SNB findings could lead to over or under treatment.  
 
Evidence of the clinical significance of INN is limited with only one study evaluating 
the clinical outcome of patients with INN versus positive SNB (10). Several authors 
have noted a significant association between primary cutaneous melanoma and the 
presence of INN (2, 8, 10-12). Some authors even suggest an, as yet unproven, as-
sociation between INN and melanoma of unknown primary (5).  
 
Current British Association of Dermatology/British Association of Plastic, Reconstruc-
tive and Aesthetic Surgery (BAD/BAPRAS) guidelines do not recommend a specific 
treatment option for INN in SNB (13). MSLT-I classified INN as SNB negative how-
ever they did not analyse these patients as a specific subgroup (14). Current stand-
ard practice in the UK sees patients with INN treated as SNB negative.  
 
The aim of this paper is to evaluate the clinical significance of INN in patients who 




This study was carried out at the Christie Hospital in Manchester, UK. Patients with 
malignant melanoma confirmed on excision of primary tumour who underwent a SNB 
between November 1999 and June 2012 were retrospectively analysed from a pro-
spectively collected database. Indication for SNB was a primary tumour Breslow 
thickness of 1-4mm, or patients with tumours less than 1mm with additional high risk 
factors including ulceration, high mitotic count, perineural spread, Clark level IV or 
greater. All patients undergoing SNB had clinical disease excluded through examina-
tion and staging CT.  
 
SNB was carried out using a standard triple diagnostic technique with lymphoscintig-
raphy, blue dye and gamma probe assessment. Histopathological assessment of the 
lymph nodes were performed using a standardised method, as recommended by the 
European Organisation for Research and Treatment of Cancer (EORTC) (15). This 
involved a dedicated histopathology team using serial sectioning at 50 microns, H&E 
and S100 stains with additional immunohistochemistry staining as required. Positive 
SNB results were classified as ITC, metastases 0.1-2mm and metastases >2mm in 
line with previously published studies (16,17). All patients with positive SNB under-
went completion lymphadenectomy, those that declined further surgery were ex-
cluded from the study. 
 
Data was collected with regard to demographics, location of the primary, Breslow 
thickness, histology of the SNB, local and distant recurrence and survival. All follow-
up data was added prospectively to the database. 
 
The patients were divided into SNB positive, ITC on SNB, SNB negative and INN 
groups. Patients with ITC were chosen as a separate comparative group as they 
contain the lowest burden of metastasis within a positive sentinel lymph node. INN 
identified at completion lymphadenectomy were excluded from the study. 
 
Outcome measures of nodal recurrence, distal recurrence and 5-year survival were 
used to assess the differences between the groups. Difference between INN patients 
and sentinel node positive, sentinel node negative and ITC patients were analysed. 
Recurrence and survival were calculated from the time of diagnosis of primary mela-
noma. Breslow thickness, ulceration, histological subtype and location of primary 
were all evaluated for an effect on survival. Clark level and mitotic rate were not in-
cluded in the analysis due to insufficient data. 
 
Statistical analysis was performed using SPSS (Statistical Package for the Social 
Sciences) Version 16 (IBM, USA). Estimated survival was calculated using Kaplan-
Meier curves. Significance was calculated using log rank tests and chi squared tests 
for categorical data. A p-value of <0.05 was considered significant. 
 
Results 
Between November 1999 and June 2012, 353 patients with a median age of 53.5 
years, underwent SNB for MM and were included in the study. Demographics of all 
included patients are summarised in Table 1. 
 
Forty seven patients (13%), 16 male and 31 female, with a median age of 52.5, had 
INN detected within their SNB. Median Breslow thickness was 1.5mm (range 0.6-
4mm).  
 
203 patients (58%) were sentinel node negative. 103 patients were sentinel node 
positive (29%), of these 13 (4%) had isolated tumour cells, 63 (18%) had metastases 
0.1-2mm, and 27 (8%) had metastases >2mm. A higher Breslow thickness was sig-
nificantly associated with a positive sentinel node biopsy (p<0.05). There was no sig-
nificant difference in any other demographic characteristic between any of the 
groups. 
 The presence of nodal naevi was more commonly associated with the female sex 
and upper limb primaries however these differences were not significant (p>0.05). 
INN were not significantly associated with any other demographic characteristic. 
 
Breslow thickness, ulceration, histological subtype and location of primary were not 
significant for an effect on survival or recurrence in any of the groups. 
 
Nodal Recurrence 
Less than 1% of sentinel node negative patients and no INN or ITC patients devel-
oped nodal recurrence with no significant difference in recurrence between these 
groups (p>0.05). There was a significant difference in nodal recurrence between 
SNB positive and INN patients (p<0.01). 
 
Distant recurrence 
There was no significant difference in the frequency of distant recurrence between 
INN and SNB negative patients. There was a significant difference in distant recur-
rence between INN and SNB positive patients (p<0.001). There was also a signifi-
cant difference between INN and ITC patients in distant recurrence (p<0.05) as illus-
trated in Figure 2. 
 
Survival 
The 5 year survival rate of the different groups were: SNB negative patients 97.5%; 
INN patients 100%; ITC patients 80.8%; Mets 0.1-2mm 75.6%; Mets >2mm 43.7%. 
The survival curves are illustrated in Figure 2. There was a significant difference be-
tween INN patients and SNB positive patients as a whole (p<0.001) as illustrated in 
Figure 3 and with each positive group. There was also a significant difference in sur-
vival between positive patients with smaller, <2mm metastases and larger, >2mm 
metastases (p<0.05). There was no significant difference in survival between INN 
and SNB negative patients. 
 
Discussion 
The prevalence of 13% of patients with intra nodal naevi in sentinel node biopsy in 
this study is in line with previously reported rates (2,5,6). No significant factors were 
to be associated with the presence of INN in this study. However there was a trend 
towards significance of upper limb primary tumours which is in keeping with previous 
studies which have found INN to be more commonly associated with axillary nodes 
(2,3,18) and lower limb tumours to be negative predictive factors (10). Previous stud-
ies have found an association with tumour thickness (12), which we did not observe. 
 
The presence of INN can pose a significant histological challenge. Melanoma cells 
may demonstrate a nevoid pattern with a lack of clearly atypical cells making them 
difficult to differentiate from benign cells (19-22). Moreover, loss of expression in 
HMB-45 can occur in approximately 20% of melanoma metastases (23). INN are of-
ten identified by location in the trabeculae or lymph node capsule, however aggre-
gates have been identified within parenchyma and nodal sinuses (4,24,25).  
 
In this study there were no false negatives amongst INN patients with no patients up-
staged following nodal recurrence. This suggests that the standardised EORTC 
method for differentiating INN from metastatic deposits is robust and accurate when 
conducted correctly (15). 
 
INN are known to be more common in melanoma than in other primary tumours (2). 
Theories for this include: mechanical disruption by the primary tumour forcing benign 
naevi into lymphatic channels (2,4) or an increased body melanocyte-load increasing 
the initial risk of melanoma (26).  
 Evidence for the clinical significance of INN in melanoma is limited with only one pre-
viously reported case of lymph node melanoma arising from dysplastic naevus de-
posits (27). Nodal naevi have been shown to harbour the BRAF V600E mutation (28) 
however this is commonly seen in benign melanocytes with no associated link be-
tween this and malignant INN change. Some have hypothesised that INN may pro-
vide a clue to metastatic melanoma of unknown primary (5,27) however this is also 
unproven. 
 
To date only one study has attempted to evaluate the significance of INN in SNB for 
melanoma (10). The authors found that patients with INN had significantly better 5-
year survival compared with SNB positive patients with no difference in survival be-
tween INN and SNB negative patients. Our study is in keeping with this; however  we 
also found that there is a significant difference in both local and distant recurrence 
between INN and SNB positive patients whereas there is no difference when com-
pared to SNB negative patients. This should be expected given the difference in sur-
vival but these findings indicate that the underlying biology of the nodal naevi cells is 
benign, at least within the relatively short followup of this study.  
 
Interestingly we did not find any INN associated with metastatic deposits in SNB 
samples, which may provide clues to the underlying tumour biology associated with 
the primary tumours in INN. The benign nature of INN is further highlighted by the 
significant difference in both survival and distant recurrence between patients with 
INN and those with the lowest tumour burden, isolated tumour cells. We believe 
these findings confirm that patients with INN can be appropriately treated as SNB 
negative patients with no need for further treatment. 
 
Limitations of this study include the relatively short followup time which limits the ac-
curacy of any long term conclusions drawn on the behaviour of intra nodal naevi pa-
tients. A further limitation is the relatively small population size of both INN and ITC 
patients which limits the accuracy of the conclusions drawn for these groups. Further 
genetic evaluation of intra nodal naevi cells may allow their behaviour and malig-
nant/metastatic potential to be further elucidated. 
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Age (Years)  
Median 53.5 (18.5-86) 
Sex n(%)  
Male 146 (41) 
Female 207 (59) 
Follow up (months)  
Median (Range) 27 (2-169) 
Site of primary tumour  
Lower limb 127 
Upper limb 100 
Trunk 116 
Head and neck 10 
Histological subtype of primary tumour  
Nodular 97 
Superficial spreading 121 
Acral lentiginous 27 
MM unknown histology 108 
Sentinel node biopsy result  
Negative 203 
Intranodal naevi 47 
Isolated tumour cells 13 
Metastasis 0.1-2mm 63 
Metastasis >2mm 27 
Breslow thickness of primary (mm)  
Median (Range) 1.8 (0.4-12) 












Figure 1: Histology slide illustrating an INN within a lymph node capsule 
 
Figure 2: Kaplan-Meier curve illustrating difference in distant recurrence between pa-
tients with negative sentinel node biopsy, intra nodal naevi and isolated tumour cells 
 
Figure 3: Kaplan-Meier curve illustrating difference in survival between patients with 
negative sentinel node biopsy, INN, ITC, metastases 0.1-2mm, and metastases 
>2mm 
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